eliquis apixaban logo eliquis apixaban logo eliquis apixaban logo

This information is intended for healthcare professionals based in the UK.

If you are not a healthcare professional in the UK, please click here.

For Prescribing and Adverse Event reporting information, click here.

desk-img mob-img

ELIQUIS (apixaban) dosing for patients with DVT / PE

Start twice daily, stay twice daily for your patients with DVT / PE1

ELIQUIS indications1

Dose1

knee-icon

Morning*

knee-icon

Night*

knee-iconlung-icon

VTE / PE treatment: treatment of DVT and PE in adults

Day 1–7:
10 mg BD

5mgTablet-icon5mgTablet-icon
ELIQUIS 5 mg x2

5mgTablet-icon5mgTablet-icon
ELIQUIS 5 mg x2

Day 8 onwards:
5 mg BD
for at least 3 months


knee-icon
ELIQUIS 5 mg

knee-icon
ELIQUIS 5 mg

combined-Lung-knee-icon

Prevention of recurrent DVT / PE: prevention of recurrent DVT and / or PE in adults following completion of 6 months of treatment with ELIQUIS 5 mg BD or with another anticoagulant treatment for DVT or PE

2.5 mg

knee-icon
ELIQUIS 2.5 mg

knee-icon
ELIQUIS 2.5 mg

The duration of overall therapy should be individualised after careful assessment of the treatment benefit against the risk for bleeding.1
* Tablets shown are not actual size.
† Short duration of treatment (at least 3 months) should be based on transient risk factors (e.g. recent surgery, trauma, immobilisation).1

Diagnosemethoden

Dosing could differ for some patients with renal or hepatic impairment1

ELIQUIS has established efficacy and safety in
DVT / PE1

View information to assist your daily practice, including adverse reactions, contraindications and interactions


ELIQUIS (apixaban) SmPC

Please click here to access the ELIQUIS SmPC.

ELIQUIS (apixaban) Patient Information Leaflet

Please click here to access the ELIQUIS Patient Information Leaflet.

BD = Twice Daily   
DVT = Deep Vein Thrombosis   
INR = International Normalised Ratio   
LMWH = Low Molecular Weight Heparin   
NVAF = Non-Valvular Atrial Fibrillation   
PE = Pulmonary Embolism   
VTE = Venous Thromboembolic Events

Reference

  1. ELIQUIS® (apixaban) Summary of Product Characteristics.